MX2023009728A - Vacuna recombinante meningococica b. - Google Patents

Vacuna recombinante meningococica b.

Info

Publication number
MX2023009728A
MX2023009728A MX2023009728A MX2023009728A MX2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A
Authority
MX
Mexico
Prior art keywords
protein
meningococcal
fhbp
antigens
present disclosure
Prior art date
Application number
MX2023009728A
Other languages
English (en)
Inventor
Laurence Quemeneur
Nadège Arnaud-Barbe
Vinod Balhara
Raffaella Iantomasi
Marie- Pierre Kazek-Duret
Jacqueline Mccluskey
Bachra Rokbi
John SHIVER
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MX2023009728A publication Critical patent/MX2023009728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se refiere a una composición inmunógena que comprende una combinación de antígenos meningocócicos que comprende al menos una proteína de unión al factor H proteína A (fHBP), al menos una proteína fHBP B, al menos una proteína adhesina A de Neisseria (NadA), y al menos una vesícula de membrana externa extraída con detergente (dOMV). Los antígenos meningocócicos pueden ser de Neisseria meningitidis del serogrupo B. La combinación de antígenos proporcionaba una amplia cobertura de cepas bacterianas. Además, la presente descripción se refiere al uso de la composición inmunógena en métodos para producir una respuesta inmunitaria.
MX2023009728A 2021-02-19 2022-02-18 Vacuna recombinante meningococica b. MX2023009728A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305211 2021-02-19
US202163172885P 2021-04-09 2021-04-09
PCT/US2022/016894 WO2022178196A1 (en) 2021-02-19 2022-02-18 Meningococcal b recombinant vaccine

Publications (1)

Publication Number Publication Date
MX2023009728A true MX2023009728A (es) 2023-08-30

Family

ID=80595537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009728A MX2023009728A (es) 2021-02-19 2022-02-18 Vacuna recombinante meningococica b.

Country Status (11)

Country Link
US (1) US20220265805A1 (es)
EP (1) EP4294432A1 (es)
JP (1) JP2024507828A (es)
KR (1) KR20230147075A (es)
AU (1) AU2022223712A1 (es)
CA (1) CA3211240A1 (es)
CO (1) CO2023010612A2 (es)
IL (1) IL305313A (es)
MX (1) MX2023009728A (es)
TW (1) TW202245836A (es)
WO (1) WO2022178196A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5494808A (en) 1994-09-15 1996-02-27 Merck & Co., Inc. Defined medium OMPC fermentation process
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TR200101055T2 (tr) 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
CN1391483A (zh) 1999-09-24 2003-01-15 史密丝克莱恩比彻姆生物有限公司 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用
WO2001064922A2 (en) 2000-02-28 2001-09-07 Chiron Spa Heterologous expression of neisserial proteins
ES2388848T3 (es) 2001-01-23 2012-10-19 Sanofi Pasteur Inc. Vacuna meningocócica polivalente preparada con un conjugado de polisacárido y proteína
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
AU2016273825A1 (en) * 2009-10-27 2017-01-05 Novartis Ag Modified meningococcal fHBP polypeptides
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
CN102869377A (zh) * 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
US9827300B2 (en) 2010-03-30 2017-11-28 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
CA2803239A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CN103842008B (zh) 2011-09-26 2016-09-14 泰尔茂株式会社 液体注入器具
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2015017817A1 (en) 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
ES2841378T3 (es) 2014-02-28 2021-07-08 Glaxosmithkline Biologicals Sa Polipéptidos fHbp meningocócicos modificados
WO2015151693A1 (ja) 2014-03-31 2015-10-08 テルモ株式会社 プレフィルドシリンジ
CA2954745A1 (en) 2014-07-17 2016-01-21 Glaxosmithkline Biologicals S.A. Modified meningococcal fhbp polypeptides
NZ729206A (en) 2014-07-23 2022-07-01 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
EP3011990A1 (en) 2014-10-21 2016-04-27 Sulzer Mixpac AG Dual-chamber syringe
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020165711A1 (en) * 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof

Also Published As

Publication number Publication date
KR20230147075A (ko) 2023-10-20
US20220265805A1 (en) 2022-08-25
IL305313A (en) 2023-10-01
WO2022178196A1 (en) 2022-08-25
CO2023010612A2 (es) 2023-09-08
EP4294432A1 (en) 2023-12-27
CA3211240A1 (en) 2022-08-25
AU2022223712A9 (en) 2024-02-22
JP2024507828A (ja) 2024-02-21
AU2022223712A1 (en) 2023-10-05
TW202245836A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
CY1117957T1 (el) Συμπληρωμενο omv εμβολιο εναντι μηνιγγιοκοκκου
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
Locht et al. New pertussis vaccination approaches: en route to protect newborns?
NO20071609L (no) Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker
JP2004512269A5 (es)
JP2011500662A5 (es)
TW200722101A (en) Novel composition
RU2007128332A (ru) Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
RU2010138815A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
EP2544714A1 (en) Vaccine composition
CL2011002369A1 (es) Una composicion inmunogenica que comprende: un sacarido capsular neumococico conjugado, incluyendo sacarido depolimerizado de serotipo 18c; y antigeno de proteina de union a factor h (fhbp) meningococico, pero sin incluir vesiculas de membrana meningococida. y metodo de preparacion de la composicion.
JP6177206B2 (ja) 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
RU2010119947A (ru) Составы менингококковых вакцин
EP2117585A1 (en) Compositions comprising polysaccharide conjugates and their use as vaccines
TWI630915B (zh) 無細胞百日咳疫苗
MX2023009728A (es) Vacuna recombinante meningococica b.
AU2008327827B2 (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
RU2015100889A (ru) Вакцины для менингококка серогруппы х
JP2002537352A5 (es)
Fukasawa et al. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice
Van Den Dobbelsteen et al. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine
MX2023004729A (es) Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
Høiby et al. Serological responses in Norwegian adult volunteers to a meningococcal 15: P1. 16 outer membrane vesicle vaccine (phase II studies)
AR124923A1 (es) Vacuna recombinante meningocócica b
AU2010247253A8 (en) Method for detoxification of lipopolysaccharide (LPS) or of lipid A of gram-negative bacteria